How patients experience psoriasis: results from a European survey
|
|
- Brittney Clark
- 8 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE JEADV (2005) 19 (Suppl. 3), 2 6 DOI: /j x How patients experience psoriasis: results from a European survey Blackwell Publishing, Ltd. S Fouéré, L Adjadj,* H Pawin Department de Dermatologie and Vénérologie, Hôpital St Louis, Paris, France, Galderma International, La Défense, France and Private Practice, Chaussée de la Muette, Paris, France, *Corresponding author: Galderma International, Tour Europlaza, La Défense, France, tel ; fax ; lucie.adjadj@galderma.com ABSTRACT Background Most of the psoriasis that affects the European population is treated with topical preparations. Compliance rates, however, are known to be quite low. Objective To provide an update on how psoriasis is experienced by patients and how well these patients comply with prescribed topical treatment. Methods This was an observational and transversal survey conducted in 1281 patients with psoriasis. Patient input alone formed the basis of the study. Participants were contacted through the national psoriasis patient associations in France, the United Kingdom, Belgium, Germany and the Netherlands. Results The study showed that 32% of the patients suffer currently from psoriasis in the face, skin folds and genital areas areas very sensitive to topical treatments. Most of the patients (74%) considered their psoriasis as at least moderately severe, and 73% stated not to comply with their current treatment. Lack of efficacy and messiness of the treatment were the main reasons for non-compliance, an element that is especially important for the use in sensitive areas such as the face, skin folds and genitalia. Conclusion The present survey confirmed that cosmetic acceptability is, together with efficacy and safety, a very important aspect of a successful treatment of psoriasis. Key words: compliance, inflammatory skin disease, psoriasis, quality of life, topical treatments Received 2 September 2005, accepted 12 September 2005 Introduction Psoriasis affects 1 5% of Europeans overall, with rates as high as 6% in France and Germany. 1 3 The disease afflicts men and women equally and is present in all races and socio-economic classes and usually begins in the early adulthood. 4,5 Heredity is strongly involved in the pathogenesis, and a series of genetic susceptibility loci have been described. 4 6 Psoriatic affliction varies greatly among patients, and over time in the same patient. It is thus very difficult to quantify, especially for its psychological impact. The disease complicates millions of daily lives and disrupts countless interpersonal relationships. 6,7 Hence efforts are ongoing to find suitable instruments to measure psoriasis impact in patients quality of life 8 including numerous severity-scoring indices. These scores, however, do not relate to the patients personal history with psoriasis and they tell us nothing about their perception of treatment. For instance, it is of notice that even if most patients qualify their psoriasis as severe, the non-compliance rate with treatments is currently estimated as close to 40%. 8,9 The reasons for such a discrepancy have not been investigated so far, yet it is crucial to understand them to provide patients with more acceptable treatments or regimens. In order to shed light on these ill-understood aspects of psoriasis, we undertook a patient s survey addressing these aspects of disease history and treatment perception generally overlooked by studies of different methodology. Methods A master questionnaire was prepared in French and translated into German, English and Dutch, and was sent to psoriasis patient associations in the United Kingdom, Germany, the Netherlands, Belgium and France. The national associations offered the questionnaires randomly, with an introductory letter, European Academy of Dermatology and Venereology
2 How patients experience their psoriasis 3 to their members. All answers were translated into English and entered into a specifically designed database for this study. The survey asked about sociodemographic variables (age, sex, family, living arrangements and education level), medical data (history, location, duration and perceived severity of psoriasis) and treatment data (current and past treatments, compliance with these treatments as measured against the PMAQ-3w scale used already by Duong et al. and Child et al. reasons for non-compliance, perceived necessary measures to implement in order to increase compliance) All statistical tests were two-sided, with a significance level of 5%. Continuous variables grouped by country and overall were described using the mean, median, standard deviation and extreme values. Discontinuous variables were described by the documented frequency of each modality, both in individual countries and overall. Quantitative data were first checked for normality and homoscedasticity of residues, and an analysis of variance was performed on data that were both normal and homoscedastic. For data that were non-normal and nonhomoscedastic, the non-parametric Wilcoxon and Kruskall, and Wallis tests were employed. Qualitative group data were compared using a chi-squared test, when the data were reasonably approximated by a normal function. Fisher s exact test was performed on non-normal data. Results The survey was conducted between November 2002 and February One thousand two hundred and eighty-one (1281) patients responded, representing more than 50% of the patients initially contacted. This rate was more or less the same for all five countries. Demographic information is depicted in Table 1. The mean age of patients was 51.7 ± 12 years. The mean duration of the respondents psoriasis was 25.2 (± 12.79) years overall. The mean age for psoriasis onset was with ± years, more or less the same throughout the five countries. As expected, most patients reported suffering from psoriasis on their scalp, elbows, knees, ears, nails and backs. National variations were not generally wide: more than 60% of UK patients had nail psoriasis, compared with 40% of French and Belgian patients, whereas no Dutch patient reported psoriasis on the buttocks, an area affected in about 10% of patients from other countries. Interestingly, 32% of patients reported psoriasis of the genitals and 29% on the face. Psoriasis inversa was prevalent, with a mean 36% for skinfolds involvement. On a psychological level, 28% of all patients thought they had very severe psoriasis, and another 46% judged it somewhat severe. French patients were the most anxious, with only 14% saying their disease was not severe and with the British patients being the least worried: 45% qualified their psoriasis as not severe. Results for the physical impact were similar to the above findings, corroborating the belief that physical impact has a direct influence on the psychological level (Table 2). Sixty-seven percent (67%) of all treatments were prescribed by dermatologists; generalists (GPs) accounted for 28% of all prescriptions except in the UK, where more prescriptions (60% vs. 34% by dermatologists) were written by GPs. Detailed results are shown in Table 3. Seventy percent (70%) of all patients used a topical preparation. The most widely prescribed topical treatments were vitamin D analogues (63%), corticosteroids (57%), salicylic acid (17%) and retinoids (4%). These results include topical treatments used alone or in combination with other topical treatments. Forty-two percent (42%) used a topical treatment in combination with other therapies: phototherapy (36%), oral drugs (38%) or alternative treatments such as sun sea stays or baths. Table 4 provides further information. Table 1 Patient demographics Total number of patients Mean age (years) (Standard deviation) (14.73) (13.68) (15.21) (14.46) (14.84) (14.76) Gender % (N) Male 49% (109) 36% (88) 49% (147) 55% (145) 52% (128) 48% (617) Female 51% (115) 64% (158) 51% (154) 45% (117) 48% (117) 52% (661) Is cohabiting % (N) n/a n/a n/a 89% (230) 81% (190) 85% (420) Has children % (N) 70% (156) 64% (155) 73% (218) n/a n/a 69% (529) If yes, is the main child carer % (N) 47% (72) 42% (56) 38% (81) n/a n/a 42% (209) Education Primary education % (N) 36% (79) 3% (8) 19% (58) 18% (46) 9% (22) 17% (213) Secondary education % (N) 40% (87) 53% (125) 52% (155) 47% (122) 51% (126) 49% (615) University degree % (N) 25% (54) 44% (103) 29% (87) 35% (92) 40% (99) 34% (435) n/a, not applicable.
3 4 Fouéré et al. Table 2 Patient rating of psychological and physical appearance impact of psoriasis Total number Psychological impact NP Very severe 85 (38%) 26 (11%) 118 (39%) 80 (31%) 45 (18%) 354 (28%) Somewhat severe 104 (46%) 105 (44%) 140 (47%) 122 (47%) 116 (47%) 587 (46%) Not severe 36 (16%) 109 (45%) 41 (14%) 60 (23%) 84 (34%) 330 (26%) Physical impact NP Very severe 103 (46%) 20 (8%) 131 (44%) 96 (37%) 57 (23%) 407 (32%) Somewhat severe 85 (38%) 118 (49%) 125 (42%) 111 (42%) 122 (50%) 561 (44%) Not severe 35 (16%) 105 (43%) 42 (14%) 55 (21%) 64 (26%) 301 (24%) NP, not provided. Table 3 Distribution of psoriasis topical treatments among prescribers Total number Prescribed by No answers GP 39 (10%) 198 (60%) 75 (16%) 93 (37%) 50 (23%) 455 (28%) Dermatologist 321 (86%) 112 (34%) 379 (79%) 124 (49%) 159 (74%) 1095 (67%) Other 14 (4%) 18 (5%) 24 (5%) 35 (14%) 5 (2%) 96 (6%) Table 4 Current use of a second psoriasis treatment other than topical in patients using topical treatments Total number No 78 (44%) 107 (61%) 130 (55%) 103 (64%) 97 (66%) 515 (58%) Yes 99 (56%) 68 (39%) 107 (45%) 57 (36%) 49 (34%) 380 (42%) If answered yes the following treatment was used Oral 21 (21%) 28 (41%) 43 (40%) 30 (53%) 23 (47%) 145 (38%) Phototherapy UVA/UVB 61 (62%) 11 (16%) 26 (24%) 15 (26%) 23 (47%) 136 (36%) Complementary 28 (28%) 21 (31%) 50 (47%) 17 (30%) 11 (22%) 127 (33%) Other (including sun sea stays, baths, immunosuppressive, etc.) 9 (9%) 21 (31%) 23 (21%) 2 (4%) 5 (10%) 60 (16%) On average, 73% of the patients reported not complying with their treatment. Differences were not significant between countries (Table 5). The compliance was slightly higher for vitamin D derivatives (57%) compared to corticosteroids (50%) and salicylic acid (41%). Seven percent (7%) responded spontaneously in free-text answers that they only applied their medication when they thought they needed it. Main reasons for non-compliance were: low efficacy as rated by 27% of patients; poor cosmetic characteristics (sticky sensation after treatment application) as believed by 29%; time consuming (long time to rub in the topical treatment) as stated by 26% (fig. 1). Fifteen percent (15%) of the patients also mentioned that side-effects lead to non-compliance. Even if the majority of patients were non-compliant with their topical treatment, 61% reported that they were somewhat satisfied with their topical treatment and 19% very satisfied. Twenty percent were not satisfied. Patients were asked through an open question to indicate what they would like to see improved in their topical treatment in order to be more compliant. The following proposals were made: better efficacy, less greasy, sticky and smelly treatment and less side-effects. Discussion and conclusion Psoriasis is still one of the most important diseases in dermatological practice because it is so common, produces significant morbidity and has profound effects on patient s
4 How patients experience their psoriasis 5 Table 5 Distribution of fully compliant patient* with regard to their compliance for psoriasis topical treatments P-value Total number NP No 56 (61%) 60 (71%) 108 (77%) 58 (77%) 54 (76%) 336 (73%) Yes 36 (39%) 24 (29%) 33 (23%) 17 (23%) 17 (24%) 127 (27%) *Fully compliant patients were those who strictly respected the prescription during the 3 later days and last weekend. NP, not provided. fig. 1 Main reasons for non-compliance. quality of life. Previous research confirmed that more than 80% of patients suffering from the disease expressed difficulties in establishing social contacts and relationships being the worse aspect of their psoriasis. 12,13 However, until now much more attention has been paid to dermatologists views on psoriasis therapy than those of patients. Since several years now, attempts have been made to remedy and the concept of quality of life was developed from an array of information about physical, social and psychological wellbeing and two categories of questionnaires are currently in use: general health and skin-specific disease surveys But still, little quantitative information is available on subjects such as body parts affected, satisfaction or non-satisfaction with treatments and reasons thereof, degree of compliance and factors influencing it. Hence, the present survey intended to investigate the actual psoriasis situation from a patient point of view. Observations made about the burden and location of the disease somewhat contradict those made in textbooks, earlier surveys and epidemiological studies For instance, more than 30% of the patients reported psoriasis of the genitals and nearly 30% reported psoriasis on the face, locations one does not generally consider as frequently affected. Likewise, over a third of patients suffered from psoriasis inversa, which is generally believed to affect less than 10% of psoriasis patients. Most of the patients suffered from psoriasis on their scalp, elbows, knees, ears, nails and back. With 70% of the patients rating their psoriasis as at least somewhat severe, this survey confirms that patient perception of their psoriasis is different from that of their doctors. However, it needs to be indicated that the respondents to our survey were active members of psoriasis associations and therefore probably more concerned by their disease than non-members. This may also explain the high mean psoriasis duration (25 years) and the evaluation of their psoriasis as severe. The present survey further confirmed that adherence to treatment is a prerequisite for good efficacy results and this is particularly true for topical preparations. Moreover, this is especially important for the use in sensitive areas such as the face, skin folds and genitalia: when patients were asked if they complied or not with their treatment, the large majority (73%) reported not to comply. These figures are not in accordance with other studies results that generally revolve around a 40 50% rate. 8,9,13 In these studies however, the definitions and evaluation tools to measure non-compliance were different from the one we used. The fact that more than 50% of the patients complied when treated with a vitamin D derivate (57%) or with corticosteroids (50%) seems to indicate that these medications are better accepted than for instance salicylic acid-based specialties or anthralin/dithranol regimens. The main reasons given by patients for not complying were lack of efficacy and poor cosmetic characteristics of the treatments. The cosmetic aspect of treatment is also very important and it has a major impact on the patients compliance. When patients were asked to indicate possible solutions to increase their compliance, higher efficacy and lower greasiness were the main suggestions. This is particularly interesting, considering that patients who completed the survey have a long experience of different treatments and are therefore more demanding and critical. Even if a certain reporting bias was unavoidable in the study, patient-based compliance studies like this are of extreme value. They focus on the day-to-day opinions of psoriasis sufferers themselves and disclose significant elements about current disease and treatment perception, thus indicating future investigation pathways, to design better accepted topical treatments.
5 6 Fouéré et al. Acknowledgements We would like to thank the patients for the time they spent completing the survey, the physicians for their participation, the National Psoriasis Associations of Belgium, France, Germany, Netherlands and United Kingdom and their chairmen for their support. References 1 Finzi AF, Benelli C. A clinical survey of psoriasis in Italy: 1st AISP report. Interdisciplinary Association for the Study of Psoriasis. J Eur Acad Dermatol Venereol 1998; 10: Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: Stern RS. Epidemiology of psoriasis. Dermatol Clin 1995; 13: National Psoriasis Foundation (1999) What is psoriasis? (Last accessed: 29 October 2003). 5 Recchia G, Urbani F, Tasin L et al. Epidemiology of psoriasis: casecontrol study in the province of Trentino (preliminary reports). Acta Derm Venereol (Stockh) 1989; 146 (Suppl.): Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an alogorith-based approach for primary care physicians. Am Fam Phys 2000; 61: Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16: Richards HL, Fortune DG, O Sullivan TM et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: Van de Kerkhof PC, de Hoop D, de Korte J et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: Duong M, Piroth L, Grappin M et al. Evaluation of the patient medication adherence questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regiments. HIV Clin Trials 2001; 2: Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in southeast London. Br J Dermatol 1999; 141: Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1999; 41: McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996; 34: Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: Rapp SR, Feldman SR, Exum ML, Fleischer AB. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: Farber E, Bright R, Nall M. Psoriasis: a questionnaire survey of 2144 patients. Arch Derm 1968; 98:
Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features
DOI: 10.1111/j.1468-3083.2011.04196.x JEADV ORIGINAL ARTICLE Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features E. Altobelli,, *
More informationKey words: Psoriasis, Calcipotriol, Tazarotene. tazarotene. 16 ( 4 ) tazarotene calcipotriol ( 22 : 23-34, 2004)
In the treatment of plaque psoriasis, tazarotene was known to be effective, but its efficacy in a Taiwanese population has not been reported. Our purpose was to compare the efficacy, side effects and the
More informationNail psoriasis in Germany: epidemiology and burden of disease M. Augustin, K. Reich,* C. Blome, I. Schäfer, A. Laass and M.A.
EPIDEMIOLOGY AND HEALTH SERVICES RESEARCH BJD British Journal of Dermatology Nail psoriasis in Germany: epidemiology and burden of disease M. Augustin, K. Reich,* C. Blome, I. Schäfer, A. Laass and M.A.
More informationGP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
More informationCLINICAL BRIEFS. Unmet Needs in the Management of Plaque Psoriasis
CLINICAL BRIEFS Unmet Needs in the Management of Plaque Psoriasis A review of recently published data with an analysis for managed care decision makers Supplement to Volume 18, No. 1 Supplement 1 January
More informationPreetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology
International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationScience > MultiClear. How the MultiClear works?
Science > MultiClear How the MultiClear works? Treatment of Psoriasis by UVB is a common, effective and respected therapy for more than 100 years.[1] Narrow band UVB light (peak 296-313 nm) has been clinically
More informationX-Plain Psoriasis Reference Summary
X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects
More informationCLINICAL BRIEFS. Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis. By Amy Krajacic
CLINICAL BRIEFS Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis By Amy Krajacic Senior Medical Editor, Custom Publications MediMedia USA, Yardley, Pa. A review of recently
More informationImpact of Psoriasis on Quality of Life at Hera General Hospital in Makkah, Saudi Arabia
Clinical Medicine and Diagnostics 2016, 6(1): 7-12 DOI: 10.5923/j.cmd.20160601.02 Impact of Psoriasis on Quality of Life at Hera General Hospital in Makkah, Saudi Arabia Mohammad I. Fatani 1,*, Taha H.
More informationPsoriasis Treatment Transition Pathway
Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways
More informationThe RAND 36-Item Health Survey
The RAND 36-Item Health Survey Introduction The RAND 36-Item Health Survey (Version 1.0) laps eight concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationComparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne. Abstract
Original Article Comparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne Soudabeh Tirgar Tabari, MD Ali Akbar Moghadam Nia, PharmD Karimollah Hajian Amirmajid
More informationPsoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence
1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,
More informationTOPICAL TREATMENTS FOR PSORIASIS
TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you
More informationPatient reported symptoms of psoriasis: results from the Psoriasis SELECT Patient Study
Patient reported symptoms of psoriasis: results from the Psoriasis SELECT Patient Study Zhang J 1, Swensen A 1, DiBonaventura M, Pierce A 3, Nyirady J 1 1 Novartis Pharmaceuticals Corporation, East Hanover,
More informationThe efficacy of a far erythemogenic dose of narrow- band UVB phototherapy in chronic plaque type psoriasis
1 The efficacy of a far erythemogenic dose of narrow- band UVB phototherapy in chronic plaque type psoriasis ผ ว จ ย Rutsanee Akaraphanth MD, Yotsinee Kittipavara MD, Nataya Voravutinon MD, Usa Wachiratarapadorn
More informationEffectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris A Prospective Study
Pharmacology and Treatment Dermatology 27;214:68 76 DOI: 1.1159/96916 Received: October 13, 25 Accepted: March 3, 26 Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity
More informationDevelopment and Validation of a Screening Questionnaire for Psoriatic Arthritis
Development and Validation of a Screening Questionnaire for Psoriatic Arthritis Dafna D. Gladman 1, Catherine T. Schentag 1, Brian D. Tom 2, Vinod Chandran 1, Cheryl F. Rosen 1 Vernon T. Farewell 2 1 University
More informationPATIENT RESOURCES: PSORIASIS
PATIENT RESOURCES: PSORIASIS Psoriasis is a persistent skin disorder in which there are red, thickened areas with silvery scales, most often on the scalp, elbows, knees, and lower back. Some cases, of
More informationPOSITION PAPER. National Psoriasis Foundation. ** Present or past member of the Board of the National Psoriasis
POSITION PAPER Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating
More informationD.RIGOPOULOS, D.IOANNIDES,* D.KALOGEROMITROS, S.GREGORIOU AND A.KATSAMBAS
British Journal of Dermatology 24; 151: 171 175. DOI: 1.1111/j.1365-2133.24.628.x Therapeutics Pimecrolimus cream 1% vs. betamethasone 17-valerate Æ1% cream in the treatment of seborrhoeic dermatitis.
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationProgress in developing and implementing stepped-care psychological support for people with psoriasis
Progress in developing and implementing stepped-care psychological support for people with psoriasis Mark A Turner, Lucy Moorhead, Anna Simpson, Karina Jackson Abstract Psoriasis is an inflammatory, chronic,
More informationAnalysis of Factors Influencing Clinical Types of Psoriasis Vulgaris
대 한 건 선 학 회 지 제 5 권, 제 1 호 Journal of the Korean Society for Psoriasis Vol. 5, No. 1, 43-47, 2008 Analysis of Factors Influencing Clinical Types of Psoriasis Vulgaris Sang Eun Lee, M.D., Jung Eun Lee,
More informationPSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis
PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly
More informationHow Can We Get the Best Medication History?
How Can We Get the Best Medication History? Stephen Shalansky, Pharm.D., FCSHP Pharmacy Department, St. Paul s Hospital Faculty of Pharmaceutical Sciences, UBC How Are We Doing Now? Completeness of Medication
More informationThe Patient Journey in High Resolution
The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet
More informationEfficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong
ORIGINAL ARTICLES Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong Drs. C. W. Fung, L.Y. Chong, C.Y. Leung, C. N. Look, K.K. Lo, K. M. Ho Social Hygiene Service
More informationThe Norwegian Version of the Dermatology Life Quality Index: a Study of Validity and Reliability in Psoriatics
Acta Derm Venereol 2002; 82: 347 351 CLINICAL REPORT The Norwegian Version of the Dermatology Life Quality Index: a Study of Validity and Reliability in Psoriatics CATO MØRK1, ASTRID WAHL2 and TORBJØRN
More informationFor more information, please contact the National Psoriasis Foundation at 800-723-9166 or
For more information, please contact the National Psoriasis Foundation at 800-723-9166 or www.psoriasis.org. PSORIASIS 101: LEARNING TO LIVE IN THE SKIN YOU RE IN is part of an awareness program to educate
More informationBACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes
BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective
More informationPresented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention
Factors Associated with Non-Adherence to Antiretroviral Therapy among Patients Attending HIV Care and Treatment Clinics in Kenya, Namibia, and Tanzania Harriet Nuwagaba-Biribonwoha, Sherri Pals, Daniel
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationAcne. Objectives. Conflicts of Interest. Acne 05/18/2015
Objectives Acne Jonathan A. Dyer, MD Associate Professor of Dermatology and Child Health University of Missouri Discuss acne pathogenesis Recognize common acne subtypes Implement a treatment plan based
More informationThe Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis
Clinical and Laboratory Investigations Dermatology 2005;210:194 199 DOI: 10.1159/000083509 Received: June 3, 2004 Accepted: October 4, 2004 The Psoriasis Area and Severity Index Is the Adequate Criterion
More informationL. Williamson, N. Dalbeth, J. L. Dockerty, B. C. Gee 1, R. Weatherall 2 and B. P. Wordsworth
Rheumatology ;:79 79 Advance Access publication 7 April Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked L. Williamson, N. Dalbeth,
More informationAvailable online www.jocpr.com. Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(2):736-741 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 A comparative study of efficacy and safety of combination
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationA User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS
RAOS User's Guide 2004 A User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS RAOS is developed as an instrument to assess the patients opinion about their hips/knees and/or feet and associated
More informationWhat factors determine poor functional outcome following Total Knee Replacement (TKR)?
Specific Question: What factors determine poor functional outcome following Total Knee Replacement ()? Clinical bottom line All groups derived benefit from undergoing a, reviews suggests that the decision
More informationPSORIASISforum. Initiating Narrow-band UVB for the Treatment of Psoriasis. Alice N. Do, D.O. a and John Y.M. Koo, M.D. b
PSORIASISforum Spring 2004 Vol. 10, No. 1 R E P R I N T E D F R O M A JOURNAL FOR N A T I O N A L P S O R I A S I S F O U N D A T I O N P R O F E S S I O N A L M E M B E R S Initiating Narrow-band UVB
More informationPatient Reported Outcomes
Patient Reported Outcomes 16 December 2013, Nottingham Esther van Zuuren Dermatologist, Leiden University Medical Centre Netherlands Patient Reported Outcomes A Patient Reported Outcome (PRO): any aspect
More informationPhenotypes and Classification of Psoriasis
Rheumatology 2010 Birmingham 21 April 2010 Phenotypes and Classification of Psoriasis Christopher E.M. Griffiths Abbott Centocor Incyte Galderma Janssen-Cilag Leo Pharma Lynxx Novartis Pfizer Schering-Plough
More informationNail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment
JEADV ISSN 1468-3083 Blackwell Publishing Ltd ORIGINAL ARTICLE Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment M Sánchez Regaña, G Márquez Balbás, P Umbert
More information2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life
Psoriasis: 2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life 15-25%: moderate-to-severe disease - candidates for systemic therapies - often difficult to manage
More informationPredicting Medication Compliance and Persistency
Predicting Medication Compliance and Persistency By: Jay Bigelow, President Amanda Rhodes, M.P.H., C.H.E.S., Vice President Behavioral Solutions MicroMass Communications, Inc. Introduction A widely recognized
More informationSustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis
DOI: 10.1111/j.1468-3083.2009.03211.x JEADV Blackwell Publishing Ltd ORIGINAL ARTICLE Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis
More informationQuality of Life and Illness Perception in Adult EB Clinic Patients
Quality of Life and Illness Perception in Adult EB Clinic Patients Diane Beattie, Psychologist in Clinical Training Jacinta Kennedy, Principal Clinical Psychologist Katherine Sweeney, Clinical Nurse Specialist
More informationCost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Clinical and Laboratory Investigations DOI: 10.1159/000090654 Received: July 7, 2005 Accepted after revision: August 19, 2005 Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness
More informationlength of stay in hospital, sex, marital status, discharge status and diagnostic categories. Mean age and mean length of stay were compared for the
Clinical and Demographic Characteristics of Psychiatric Inpatients admitted via Emergency and Non-Emergency routes at a University Hospital in Pakistan E.U. Syed,R. Atiq ( Departments of Psychiatry, Aga
More informationD. M. Burrage is a consultant for LEO Pharma. M Hansen is an employee of LEO Pharma. The other authors declare no conflicts of interest.
DOI: 10.1111/jdv.12174 JEADV ORIGINAL ARTICLE Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study A.
More informationMethods of Outcomes Measurement in Nail Psoriasis
Dermatology 2010;221(suppl 1):23 28 DOI: 10.1159/000316177 Published online: August 9, 2010 Methods of Outcomes Measurement in Nail Psoriasis M. Augustin a A. Ogilvie b a Center for Health Services Research
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationValidation of the Treatment Related Impact Measure for Diabetes Treatment and Device: TRIM-Diabetes and TRIM-Device
Validation of the Treatment Related Impact Measure for Diabetes Treatment and Device: TRIM-Diabetes and TRIM-Device Authors Meryl Brod President, The Brod Group Mette Hammer Associate Director, Health
More informationUltraviolet phototherapy is a first-line treatment
Review Acitretin Plus UVB Phototherapy in the Treatment of Psoriasis Bridgit V. Nolan; Brad A. Yentzer, MD; Steven R. Feldman, MD, PhD Acitretin frequently is used in conjunction with UVB phototherapy.
More informationMental Health Referral Practices and Diabetic Management at Community Medical Alliance Clinic (Bell Site) Northeast Community Clinic (NECC)
Mental Health Referral Practices and Diabetic Management at Community Medical Alliance Clinic (Bell Site) Northeast Community Clinic (NECC) MaryAnn Garcia, SUNY Downstate Medical College NMF PCLP Scholar
More informationMichael E Dewey 1 and Martin J Prince 1. Lund, September 2005. Retirement and depression. Michael E Dewey. Outline. Introduction.
1 and Martin J Prince 1 1 Institute of Psychiatry, London Lund, September 2005 1 Background to depression and What did we already know? Why was this worth doing? 2 Study methods and measures 3 What does
More informationLaser Therapy for Plaque Psoriasis
Laser Therapy for Plaque Psoriasis Policy Number: Original Effective Date: MM.02.027 12/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2015 Section: Medicine Place(s)
More informationA Comparison of Training & Scoring in Distributed & Regional Contexts Writing
A Comparison of Training & Scoring in Distributed & Regional Contexts Writing Edward W. Wolfe Staci Matthews Daisy Vickers Pearson July 2009 Abstract This study examined the influence of rater training
More informationMedication Adherence Amongst Diabetic Patients in a Tertiary Healthcare Institution in Central Nigeria
Tropical Journal of Pharmaceutical Research June 2014; 13 (6): 997-1001 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of
More informationExtended Abstract. Evaluation of satisfaction with treatment for chronic pain in Canada. Marguerite L. Sagna, Ph.D. and Donald Schopflocher, Ph.D.
Extended Abstract Evaluation of satisfaction with treatment for chronic pain in Canada Marguerite L. Sagna, Ph.D. and Donald Schopflocher, Ph.D. University of Alberta Introduction For millions of people
More informationHealth Status, Health Insurance, and Medical Services Utilization: 2010 Household Economic Studies
Health Status, Health Insurance, and Medical Services Utilization: 2010 Household Economic Studies Current Population Reports By Brett O Hara and Kyle Caswell Issued July 2013 P70-133RV INTRODUCTION The
More informationA Comparative Study of Tar and Betamethasone Valerate in Chronic Plaque Psoriasis: A Study in Thailand
A Comparative Study of Tar and Betamethasone Valerate in Chronic Plaque Psoriasis: A Study in Thailand Prasutr Thawornchaisit MD*, Kitiphong Harncharoen PhD** * Department of Medicine, Lerdsin General
More informationUnderstanding and improving communications between people with rheumatoid arthritis and their healthcare professionals. RCUKCOMM00116w February 2014
Understanding and improving communications between people with rheumatoid arthritis and their healthcare professionals RCUKCOMM00116w February 2014 This project has been funded by Roche Products Ltd &
More informationImpact of adhesive capsulitis on quality of life in elderly subjects with diabetes: A cross sectional study
Original Article Impact of adhesive capsulitis on quality of life in elderly subjects with diabetes: A cross sectional study Saumen Gupta, Kavitha Raja, Manikandan N Department of Physical Therapy, Manipal
More informationSpinal cord injury and quality of life: a systematic review of outcome measures
Systematic review Spinal cord injury and quality of life: a systematic review of outcome measures 37 37 44 Spinal cord injury and quality of life: a systematic review of outcome measures Authors Jefferson
More informationEvaluation of a Primary Care Dermatology Service: final report
Evaluation of a Primary Care Dermatology Service: final report Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO) December 2005 prepared by Chris Salisbury*
More informationMARKET ANALYSIS of ActiPatch Therapy Try & Tell Surveys
MARKET ANALYSIS of ActiPatch Therapy Try & Tell Surveys Consumers Report Pain Relief, Product Satisfaction and Intent to Buy New Behavior in Pain Management is Developing BioElectronics Corporation 4539
More informationProfiles and Data Analysis. 5.1 Introduction
Profiles and Data Analysis PROFILES AND DATA ANALYSIS 5.1 Introduction The survey of consumers numbering 617, spread across the three geographical areas, of the state of Kerala, who have given information
More informationWORKING TIME, GENDER EQUALITY, AND RECONCILING WORK AND FAMILY LIFE
FACT SHEET WORKING TIME, GENDER EQUALITY, AND RECONCILING WORK AND FAMILY LIFE EUROPEAN TRADE UNION CONFEDERATION (ETUC) FACT SHEET WORKING TIME, GENDER EQUALITY, AND RECONCILING WORK AND FAMILY LIFE 01
More informationHealth economic analyses based on register data. Psoriasis and Psoriatic Arthritis as examples
Health economic analyses based on register data Psoriasis and Psoriatic Arthritis as examples Sofia Löfvendahl Epi-center Skåne, Skåne University Hospital, Lund Lund University, Clinical Sciences Lund,
More informationObservational studies on homeopathy
Observational studies on homeopathy To healthcare providers, patients and clinicians, what matters most is not necessarily how well a treatment performs under the artificially controlled conditions on
More informationNew Developments in the Topical Management of Acne
Clinical Review New Developments in the Topical Management of Acne Abstract Adapalene 0.1%/BPO 2.5% (adapalene/bpo) gel is a novel agent for acne therapy that has recently become available in Canada. This
More informationRecall Knowledge of Biochemistry for Interns after Graduation from Medical Schools
Recall Knowledge of Biochemistry for Interns after Graduation from Medical Schools Asma Almohanna*, Hadeel Al Issa, Noran AlEssa, Turki AlOhadib, Muaawia Ahmed Hamza, Ahmed EL Tahir Idris, Gwiria Satti
More informationIs the experience and expression of living with severe MS ethnically and culturally patterned?
WHO Collaborating Centre for Palliative Care, Policy and Rehabilitation Is the experience and expression of living with severe MS ethnically and culturally patterned? Dr Jonathan Koffman Cicely Saunders
More informationARTICLE IN PRESS. Addictive Behaviors xx (2005) xxx xxx. Short communication. Decreased depression in marijuana users
DTD 5 ARTICLE IN PRESS Addictive Behaviors xx (2005) xxx xxx Short communication Decreased depression in marijuana users Thomas F. Denson a, T, Mitchell Earleywine b a University of Southern California,
More informationAtilla Soykan and Bedriye Oncu. Introduction
Family Practice Vol. 20, No. 5 Oxford University Press 2003, all rights reserved. Doi: 10.1093/fampra/cmg511, available online at www.fampra.oupjournals.org Printed in Great Britain Which GP deals better
More informationPsoriasis; a new marker for Hepatitis C among Egyptian Patients
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 761-767 http://www.ijcmas.com Original Research Article Psoriasis; a new marker for Hepatitis C among Egyptian Patients Asmaa E Mohamed 1, Samaa A Taha 2, Amal
More informationThe National Survey of Children s Health 2011-2012 The Child
The National Survey of Children s 11-12 The Child The National Survey of Children s measures children s health status, their health care, and their activities in and outside of school. Taken together,
More informationLasers that emit short pulses of UV light in
Handheld roadband UV Phototherapy Module for the Treatment of Patients With Psoriasis and Vitiligo Peter P. Rullan, MD Cosmetic Technique Short pulses of UV light in the 300- to 380-nm wavelength have
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer EUROPEAN CITIZENS DIGITAL HEALTH LITERACY REPORT Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationInternational Retirement Security Survey
International Retirement Security Survey July 00 (Copyright 00 by AARP. All rights reserved.) www.harrisinteractive.com www.intlaffairs@aarp.org Table of Contents I. Background and Objectives II. III.
More informationCorrelates of not receiving HIV care among HIV-infected women enrolling in a HRSA SPNS multi-site initiative
Correlates of not receiving HIV care among HIV-infected women enrolling in a HRSA SPNS multi-site initiative Oni J. Blackstock, MD, MHS Assistant Professor of Medicine Division of General Internal Medicine
More informationComorbidities associated with psoriasis in the Newfoundland and Labrador founder population
Comorbidities associated with psoriasis in the Newfoundland and Labrador founder population Don MacDonald, PhD(c), Wayne Gulliver, MD, FRCPC, Neil Gladney, BTech, MSc (c), Kayla D. Collins, PhD(c), Jeff
More informationPrescribing advice for the management and treatment of psoriasis
Prescribing advice for the management and treatment of psoriasis This guidance contains suggested advice for the management and treatment of patients presenting with psoriasis. This guidance applies to
More informationCLINICAL REPORT. Title of the study. Use of PSORIT-X cream shampoo in psoriasis capitis and seborrhoea capitis. Study site
IN VITRO Ltd. H-2120 Hungary, Dunakeszi, Repülőtéri út 1i. CLINICAL REPORT Title of the study Use of PSORIT-X cream shampoo in psoriasis capitis and seborrhoea capitis Study site Semmelweis University,
More informationbulletin 126 Healthy life expectancy in Australia: patterns and trends 1998 to 2012 Summary Bulletin 126 NOVEMBER 2014
Bulletin 126 NOVEMBER 2014 Healthy life expectancy in Australia: patterns and trends 1998 to 2012 Summary bulletin 126 Life expectancy measures how many years on average a person can expect to live, if
More informationLeveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles
Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology Presented by: Elisa Cascade, MediGuard/Quintiles About Elisa Cascade, VP MediGuard/Quintiles Assisted in site
More informationCLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV)
Southeast-Asian J. of Sciences: Vol. 2, No 1 (2013) pp. 101-107 CLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV) Nguyen Huu Sau and Nguyen Minh Thu
More informationTreatment costs of psoriasis in a tertiary-level clinic
Mustonen et al. BMC Health Services Research 2014, 14:344 RESEARCH ARTICLE Treatment costs of psoriasis in a tertiary-level clinic Anssi Mustonen 1,3*, Mauri Leino 1, Kalle Mattila 1, Leena Koulu 1 and
More informationCONCISE COMMUNICATION Alefacept therapy produces remission for patients with chronic plaque psoriasis
British Journal of Dermatology 2003; 148: 784 788. CONCISE COMMUNICATION Alefacept therapy produces remission for patients with chronic plaque psoriasis G.G.KRUEGER AND C.N.ELLIS* Department of Dermatology,
More informationClinical trial enrollment among older cancer patients
Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department
More informationMicroneedling therapy in atrophic facial scars: An objective assessment (publ. 01.07.2009)
Microneedling therapy in atrophic facial scars: An objective assessment (publ. 01.07.2009) Author: Imran Majid / Cutis Skin and Laser Clinic, Govt Medical College, Srinagar, India Abstract Background:
More informationContraceptive Choice & Reducing Unplanned Pregnancy. Dr Paula Briggs Consultant in Sexual & Reproductive Health, UK
Contraceptive Choice & Reducing Unplanned Pregnancy Dr Paula Briggs Consultant in Sexual & Reproductive Health, UK Demographics Liverpool, UK Conflicts Dr Paula Briggs has received funding from: MSD Bayer
More informationThe relationship between mental wellbeing and financial management among older people
The relationship between mental wellbeing and financial management among older people An analysis using the third wave of Understanding Society January 2014 www.pfrc.bris.ac.uk www.ilcuk.org.uk A working
More information